# A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

> **NCT01878617** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 660 (actual)

## Conditions studied

- Medulloblastoma

## Interventions

- **RADIATION:** Craniospinal Irradiation with boost to the primary tumor site
- **DRUG:** Cyclophosphamide
- **DRUG:** Cisplatin
- **DRUG:** Vincristine
- **DRUG:** Vismodegib
- **DRUG:** Pemetrexed
- **DRUG:** Gemcitabine
- **OTHER:** Aerobic Training
- **OTHER:** Neurocognitive Remediation

## Key facts

- **NCT ID:** NCT01878617
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-06-23
- **Primary completion:** 2028-10-13
- **Final completion:** 2031-10-13
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2025-11-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01878617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01878617, "A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01878617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*